Hydrolysis of ATP, ADP, and AMP is increased in blood plasma of prostate cancer patients
- 14 January 2019
- journal article
- research article
- Published by Springer Nature in Purinergic Signalling
- Vol. 15 (1) , 95-105
Abstract
Prostate cancer is among the major malignancies that affect men around the world. Adenine nucleotides are important signaling molecules that mediate innumerous biological functions in pathophysiological conditions, including cancer. These molecules are degraded by several ectoenzymes named ectonucleotidases that produce adenosine in the extracellular medium. Some of these ecto-enzymes can be found in soluble in the blood stream. Thus, the present study aimed to evaluate the hydrolysis of adenine nucleotides (ATP, ADP, and AMP) in the plasma blood of patients with prostate cancer. Peripheral blood samples were collected, and questionnaires were filled based on the clinical data of the medical records. The nucleotide hydrolysis was performed by Malachite Green method using ATP, ADP, and AMP as substrates. Plasma from prostate cancer patients presented an elevated hydrolysis of all nucleotides evaluated when compared to healthy individuals. NTPDase inhibitor (ARL67156) and the alkaline phosphatase inhibitor (levamisole) did not alter ATP hydrolysis. However, AMP hydrolysis was reduced by the CD73 inhibitor, APCP, and by levamisole, suggesting the action of a soluble form of CD73 and alkaline phosphatase. On microvesicles, it was observed that there was a low expression and activity of CD39 and almost absent of CD73. The correlation of ATP, ADP, and AMP hydrolysis with clinic pathological data demonstrated that patients who received radiotherapy showed a higher AMP hydrolysis than those who did not, and patients with lower clinical stage (CS-IIA) presented an elevated ATP hydrolysis when compared to those with more advanced clinical stages (CS-IIB and CS-III). Patients of all clinical stages presented an elevated AMPase activity. Therefore, we can suggest that the nucleotide hydrolysis might be attributed to soluble ecto-enzymes present in the plasma, which, in a coordinate manner, produce adenosine in the blood stream, favoring prostate cancer progression.Keywords
This publication has 32 references indexed in Scilit:
- CD73: a potent suppressor of antitumor immune responsesTrends in Immunology, 2012
- Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine ProductionThe Journal of Immunology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferationMolecular and Cellular Biochemistry, 2008
- Enzymes that hydrolyze adenine nucleotides in platelets from breast cancer patientsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Serum enzymes in head and neck cancer. IV: 5-nucleotidaseThe Journal of Laryngology & Otology, 1989
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- A direct colorimetric assay for Ca2+-stimulated ATPase activityAnalytical Biochemistry, 1986
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976